ZS Pharma

ZS Pharma ($ZSPH)
Based: Coppell, TX
IPO price: $18
Close Sept. 30: $39.23
Change: Up 118%
Raised: $107 million

Scoop: ZS Pharma's pitch to investors was fairly simple: The biotech is developing a late-stage kidney treatment with a clear path to market and an established unmet need. The company's plans to commercialize its lead treatment on its own made that story all the more resonant, and ZS Pharma has more than doubled its market value since pulling off a June IPO. The biotech's lead drug, ZS-9, is designed to treat hyperkalemia, a rise in blood potassium levels often caused by chronic kidney disease or heart failure that can lead to cardiac arrhythmia and sudden death. In top-line results from a 753-patient Phase III trial, the oral treatment met its primary endpoint of significantly lowering serum potassium levels with adverse events similar to placebo, ZS said, charting a promising dose-dependent response for hyperkalemia sufferers. With its IPO cash, the company is working through two more studies to confirm the drug's ideal dosing with plans to submit FDA and EMA applications by 2015.

For more:
ZS Pharma looks to $86M IPO to fund PhIII hyperkalemia studies
ZS Pharma bags $55M to take its kidney drug to the FDA

ZS Pharma

Suggested Articles

Plexium is launching with $28 million to build its platform and a pipeline of drugs that target the enzymes drive recognition of protein targets.

In this week's EuroBiotech Report, Healx raises $56 million, Boehringer's VC wing backs anti-cancer virus startup and Ipsen bags Blueprint drug.

In our EuroBiotech roundup this week, GammaDelta forms antibody spinout, gene therapy startup raises cash and Amsterdam plans medical business park.